SGMO - Preliminary phase 1/2 data supports Sangamo Fabry disease gene therapy candidate

Sangamo Therapeutics' (SGMO +21.4%) isaralgagene civaparvovec (ST-920) for Fabry disease was well tolerated in a phase 1/2 trial. In addition, the four patients in the trial all exhibited fabove normal alpha-galactosidase A (?-Gal A) activity. No treatment-related adverse events higher than Grade 1 and no treatment-related serious adverse events were reported. Based on the results, Sangamo has begun planning for a phase 3 trial. Isaralgagene civaparvovec, which has Orphan Drug designation, requires a one-time infusion. Sangamo reported Q3 2021 financial results this morning.

For further details see:

Preliminary phase 1/2 data supports Sangamo Fabry disease gene therapy candidate